Seeing that liver disease is rampant in this country, the Hepato-Biliary-Pancreatic Division was established in Kaohsiung Medical University Hospital in 1985 and is directed by professor Wen-Yu Chang, who has been devoted to the prevention and treatment of liver disease and stands in a pioneering position in the field of Gastroenterology and Hepatology.
Professor Chang, gathering other prominent elites, founded “Taiwan Liver Research Foundation” in 1999. In recent years, the foundation has been devoting itself to the society, providing service and promoting the concept “Prevention Rather than Cure”. On the other hand, the foundation has been helping the Hepato-Biliary-Pancreatic Division of Kaohsiung Medical University Hospital to do further research on liver disease. By using this medical organization as a platform that combines the efforts from more experts and volunteers, the threat of liver disease to the nation can be diminished and national health and welfare can be achieved.
Objectives:
1. Provide people with knowledge about liver diseases; promote treatment and prevention of liver diseases.
2. Provide checkups and care about unprivileged groups and communities.
3. Encourage and support researchers to involve in prevention and research of liver diseases.
4. Provide a platform for medical institutes and relevant academic institutes to improve the overall medical quality.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close